Mode
Text Size
Log in / Sign up
N/A Completed N=40 Randomized Single-blind Treatment

Platelet-rich Fibrin and Connective Tissue Graft in Recession Treatment

Gingival Recession
Source: ClinicalTrials.gov NCT02397122 ↗
Enrolled (actual)
40
Serious AEs
0.0%
Results posted
May 2018
Primary outcomePrimary: Vertical Recession — 3.35; 3.20; 0.38; 0.65 mm — p=0.259

Summary

The aim of the trial is to evaluate the effectiveness of coronally advanced flap (CAF)+connective tissue graft(CTG)+platelet-rich fibrin(PRF) combination in Miller I and II recession treatment by comparing with CAF+CTG. 40 patients were surgically treated either with CAF+CTG+PRF (test group) or CAF+CTG (control group). Clinical parameters of plaque index (PI), gingival index (GI), vertical recession (VR), probing depth (PD), attachment level (AL), keratinized tissue width (KTW), horizontal recession (HR), MGJ localization (L-MGJ), tissue thickness (TT) were recorded at baseline, 3 months (PS1) and 6 months (PS2) post-surgery. Root coverage (RC), complete RC (CRC), attachment gain (AG), and keratinized tissue change (KTC) were also calculated.

Outcome Measures

OutcomeResultp-value
PRIMARY
Vertical Recession
3.35; 3.20; 0.38; 0.65; 0.35; 0.65 0.259
SECONDARY
Horizontal Recession
3.8; 3; 0; 1; 0; 1 0.067
SECONDARY
Probing Depth
1; 1; 1; 1; 1; 1 0.298
SECONDARY
Attachment Level
4.5; 4; 1; 2; 1; 1.8 0.136
SECONDARY
Keratinized Tissue Width
3; 2.8; 4; 3.5; 4; 3.8 0.245
SECONDARY
Tissue Thickness
0.9; 0.9; 1.9; 1.6; 1.9; 1.5 0.946

Eligibility Criteria

Inclusion Criteria

  • Systemically healthy
  • Single Miller type I or II recession defect ≥ 3 mm localized to anterior/premolar area
  • No alveolar bone loss
  • Identifiable cemento-enamel junction
  • Probing depth ≤3mm

Exclusion Criteria

  • Smoking
  • Pregnancy
  • History of periodontal surgery in last two years
  • Mobility
  • Excessive occlusal contacts
  • Caries
  • Loss of vitality
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02397122). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search